Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system

Voyager Therapeutics (NASDAQ: VYGR) is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.

Year Invested: 2014
Location: Cambridge, Mass.

Recent News

February 13, 2017
Voyager Therapeutics Announces Lead Clinical Candidate Selection for Monogenic Form of Amyotrophic Lateral Sclerosis (ALS)

February 2, 2017
Voyager Therapeutics to Attend Upcoming Investor Conferences

January 25, 2017
Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience

Read More News

Associated Team Members

Mark Levin

Perry Karsen
Venture Partner

Philip Reilly, M.D., J.D.
Venture Partner